Interview with Gabor Somlyai, Managing Director, HYD LLC.
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
The OEP, as a central agency, performs the functions set out in legislation, carries out the tasks relating to the management of the National Health Insurance Fund, the maintenance of records, keeping financial accounts and fulfilling the reporting obligation.
The National Health Insurance Fund is supervised by the Government of Hungary, the central official organ of health insurance is managed by the Government through the Minister of Human Resources.
Healthcare services funded by the National Health Insurance Fund
Benefits in kind and cash benefits are provided by the OEP to the insured persons.
Benefits in kind includes cost-free healthcare services such as preventive examinations, primary healthcare, specialised inpatient care, specialised outpatient care, certain dental care, rehabilitation, the ambulance service, patient transport and accident-related benefits, drug reimbursement, reimbursement for medical aids, medical spa services, reimbursement of travel expenses and benefits granted on grounds of equity.
Cash benefits provided by the OEP include sickness benefit, prenatal allowance, child care fee and accident-related benefits.
The OEP has contractual relations with the healthcare providers. Investment and development costs of healthcare institutions are not covered by the Health Insurance Fund budget. The funding of these institutions is provided by their owners.
Contact
H – 1139 Budapest, Váci út 73/A.
Telefon: (+36-1) 350-2001
Fax: (+36-1) 298-2403
E-mail: oep@oep.hu
www.oep.hu
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
Hungary has been recognized as one of the largest pharmaceutical and healthcare markets in Central and Eastern Europe, and can obviously not be ignored by Roche. First of all, can…
You took over as GM back in 2008. No doubt that this was a challenging time to run a business, in particular in view of the external economic environment. Can…
The Hungarian pharmaceutical environment has been undergoing a turbulent time recently, with many new measures being implement by the Government. What are your observations, and how do you expect companies…
Assign Group started in 2002 as a small local CRO company founded in Austria; monitoring and doing minor project management only. Why was Austria chosen as the headquarters? First, it…
With approximately $90 billion flowing into the country (according to the Hungarian Investment and Trade Agency) since it abolished its centrally planned economy and transformed into an open, pro-business economy…
Taking a look at the voices of the pharmaceutical industry in Hungary, we see AIPM and MAYGOSZ as the 2 key associations. And while MAGYOSZ already represents many generic players……
IMS is a strong brand name when it comes to pharma and healthcare information worldwide. Can you please elaborate on the particularities that set the Hungarian pharmaceutical market apart from…
The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in…
Hungary is one of the largest pharmaceutical markets in the region, and has been used by Janssen-Cilag as a hub. Can you elaborate on how important Hungary is for Janssen-Cilag…
Talking to Cegedim means talking to one of the experts in local market knowledge. Can you tell our readers from your point of view what really distinguishes Hungary from other…
Looking at Boehringer Ingelheim (BI) in Hungary, at first glance we see a company with a presence of already 20 years, which basically means an entry into this market right…
See our Cookie Privacy Policy Here
